Bluejay Investor Presentation Deck

Summary ●●● ●● 00 00 Novel Proprietary Diagnostic Platform focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression Lead Symphony IL-6 Product Candidate has completed its planned clinical studies and is on track for a potential de novo FDA Marketing Application Multi-Billion Pipeline Opportunity based on efficient measurement of clinically relevant biomarkers in critical care settings Meaningful News flow with multiple opportunities to create value 2022-23 Leadership Team with deep experience in development and commercialization of novel diagnostics, strategy and finance Funded to Execute on Plan with $15.3MM in cash as of June 30, 2022 Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 18

View entire presentation